Clinical trials: Microangiopathy
Hematopoietic Stem Cell Transplantation-Associated Thrombotic Microangiopathy
Thymoglobulin® Pharmacokinetics in Patients Undergoing Hematopoietic Stem Cell Transplantation
Thymoglobulin is widely applied as serotherapy in order to prevent acute graft-versus-host disease (GvHD) and graft rejection in patients undergoing non-Human Leukocyte Antigen (HLA)-identical hematopoietic stem cell…
- Trial name
- PHASAL-GA (NCT05743400)
- Testing
- Thymoglobulin 25 milligrams (mg) Injection, blood test
- Where
- 2 sites in France
- Volunteers
- 35 people
- Sponsor
- Hospices Civils de Lyon
Thrombotic Microangiopathy
Study of Ravulizumab in Pediatric Participants With HSCT-TMA
This study will evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of ravulizumab administered by intravenous infusion to pediatric participants, from 1 month to < 18 years of age, with HSCT-TMA.
- Trial name
- NCT04557735
- Testing
- Ravulizumab, Best Supportive Care
- Where
- 26 sites in United States, Israel and 5 more
- Volunteers
- 41 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Thrombotic Microangiopathy, Hematopoietic Stem Cell Transplant
A Study Using Real-world Data to Examine Outcomes in Children and Adults Who Develop a Blood Clotting Disorder Called Thrombotic Microangiopathy (TMA) After Undergoing a Hematopoietic Stem Cell Transplant (HSCT).
The purpose of this study was to assess OS outcomes in pediatric (≥ 28 days of age at the time of HSCT-TMA diagnosis) and adult participants diagnosed with HSCT-TMA(referred to as TMA from hereon) within 52 weeks after HSCT and…
- Trial name
- ALX-TMA-502 (NCT07732361)
- Where
- 43 sites in United States, Belgium and 8 more
- Volunteers
- 307 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Thrombotic Microangiopathy, Hematopoietic Stem Cell Transplantation (HSCT)
Safety and Efficacy of Iptacopan in Patients With High-Risk Transplantation-Associated Thrombotic Microangiopathy
The goal of this clinical trial is to evaluate the efficacy and safety of Iptacopan as a second-line treatment for high-risk hematopoietic stem cell transplantation-associated thrombotic microangiopathy (TA-TMA).
- Trial name
- NCT07347990
- Testing
- iptacopan
- Where
- China
- Volunteers
- 30 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
SNAKEBITE, THROMBOTIC MICROANGIOPATHY
Incidence of Snakebite Associated Thrombotic Microangiopathy & Role of Peripheral Blood Smear as a Predictor of Clinical Outcome
The aim of this study is to find the overall incidence of thrombotic microangiopathy in snakebite victims. As we know snakebite is a common in tropical regions.
- Conditions
- SNAKEBITE, THROMBOTIC MICROANGIOPATHY, SCHISTOCYTES
- Trial name
- NCT04845022
- Where
- India
- Volunteers
- 81 people
- Sponsor
- Jubilee Mission Medical College and Research Institute
Thrombotic Microangiopathies
Defibrotide TMA Prophylaxis Pilot Trial
Thrombotic microangiopathy (TMA) is a common complication in the stem cell transplant population. Certain populations within the hematopoietic stem cell transplant (HSCT) population are at a higher risk than others.
- Trial name
- NCT03384693
- Testing
- Defibrotide
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of California, San Francisco
Hematopoietic Stem Cell Transplant Associated Thrombotic Microangiopathy (HSCT-TMA)
Single Patient Expanded Access Treatment Plan For The Investigational Product Narsoplimab
The purpose of the EAP is to provide access to hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) patients who may benefit from treatment with narsoplimab based on the medical judgement of their…
- Trial name
- NCT04247906
- Testing
- Narsoplimab
- Sponsor
- Omeros Corporation
Thrombotic Microangiopathy
Ravulizumab in Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplant
This study will evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of ravulizumab in adult and adolescent participants with hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA).
- Trial name
- NCT04543591
- Testing
- Ravulizumab, Best supportive care
- Where
- 66 sites in United States, Australia and 15 more
- Volunteers
- 148 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Thrombotic Microangiopathies, Hematopoietic Stem Cell Transplantation
Identification of Plasma Biomarkers for Early Diagnosis of Transplant-associated Thrombotic Microangiopathy
The goal of this clinical trial is to learn about plasma biomarkers of diagnosed transplant-associated thrombotic microangiopathy (TA-TMA) in patients undergoing transplantation.
- Trial name
- NCT06102694
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Thrombotic Thrombocytopenic Purpura (TTP), Immune Thrombotic Thrombocytopenic Purpura
Retrospective Epidemiological Study of Patients in the National Cohort of the French TMA Center
Immune thrombotic thrombocytopenic purpura (iTTP) is a rare, life-threatening disorder characterized by microangiopathic hemolytic anemia, severe thrombocytopenia, and ischemic organ damage due to microvascular thrombosis.
- Conditions
- Thrombotic Thrombocytopenic Purpura (TTP), Immune Thrombotic Thrombocytopenic Purpura, Thrombotic Microangiopathies, Microangiopathy, Thromboic
- Trial name
- TWILIGHT (NCT07205861)
- Where
- France
- Volunteers
- 1,200 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Thrombotic Micro-angiopathy
Therapeutic Orientation Test in Thrombotic Microangiopathy
Haemolytic and Uraemic Syndrome (HUS) is a serious disease requiring rapid diagnosis and management. The atypical HUS diagnosis has been greatly improved by anti-CS antibody (Eculizumab) wich block alternative complement pathway…
- Trial name
- TOTEM (NCT04777435)
- Testing
- Therapeutic orientation test for TMA
- Where
- 20 sites in France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Montpellier
Thrombotic Microangiopathies, Hematopoietic Stem Cell Transplantation
Efficacy and Safety Study of Narsoplimab in Pediatric Patients With High-Risk Hematopoietic Stem Cell Transplant TMA
The purpose of this study is to evaluate the safety and efficacy of narsoplimab in pediatric patients with thrombotic microangiopathies (TMA) following hematopoietic stem cell transplant (HSCT).
- Trial name
- NCT05855083
- Testing
- Biological: narsoplimab
- Where
- 16 sites in United States, Germany and 3 more
- Volunteers
- 18 people
- Sponsor
- Omeros Corporation
Thrombotic Microangiopathies, Atypical Hemolytic Uremic Syndrome
Eculizumab to Treat Thrombotic Microangiopathy/Atypical Hemolytic Uremic Syndrome -Associated Multiple Organ Dysfunction Syndrome in Hematopoietic Stem Cell Transplant Recipients
Hematopoietic stem cell transplantation (HCT)-associated thrombotic microangiopathy (TMA) is an understudied complication of HCT that significantly affects transplant related morbidity and mortality.
- Conditions
- Thrombotic Microangiopathies, Atypical Hemolytic Uremic Syndrome, Multiple Organ Dysfunction Syndrome
- Trial name
- NCT03518203
- Testing
- Eculizumab
- Where
- 3 sites in United States
- Volunteers
- 23 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Stem Cell Transplant Complications, Thrombotic Microangiopathies
Study in Adult and Pediatric Patients With HSCT-TMA
This is an observational, retrospective study designed to assess outcomes in patients diagnosed with hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) who were not treated with complement…
- Trial name
- NCT04970004
- Testing
- No intervention
- Where
- United States
- Sponsor
- Alexion Pharmaceuticals, Inc.
Thrombotic Microangiopathy, Hemolytic Uremic Syndrome
International Registry and Biorepository for TMA(Thrombotic Microangiopathy)
This registry will collect clinical data and store biosamples (seru, plasma, urine, and DNA) annually from pediatric patients with thrombotic mcroangiopathy
- Conditions
- Thrombotic Microangiopathy, Hemolytic Uremic Syndrome, Thrombotic Thrombocytopenic Purpura
- Trial name
- NCT00593229
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Northwell Health
Adenine Phosphoribosyltransferase Deficiency, AH Amyloidosis
National Registry of Rare Kidney Diseases
The goal of this National Registry is to is to collect information from patients with rare kidney diseases, so that it that can be used for research.
- Conditions
- Adenine Phosphoribosyltransferase Deficiency, AH Amyloidosis, AHL Amyloidosis, AL Amyloidosis
- Trial name
- RaDaR (NCT06065852)
- Where
- United Kingdom
- Volunteers
- 35,000 people
- Sponsor
- UK Kidney Association
TTP - Thrombotic Thrombocytopenic Purpura
Italian iTTP Registry
ItaliTTP is an observational, prospective, single-arm, national, multicenter, non-pharmacological cohort study aimed at better defining and understanding the natural history, disease severity, and clinical outcomes of patients…
- Trial name
- NCT06376786
- Where
- Italy
- Volunteers
- 132 people
- Sponsor
- Fondazione Luigi Villa
Transplant-Associated Thrombotic Microangiopathy, Neuroblastoma
Defibrotide Prophylaxis of Transplant Associated-Thrombotic Microangiopathy for Neuroblastoma
This phase II trial tests how well defibrotide works in preventing transplant-associated thrombotic microangiopathy (TA-TMA) in patients with high-risk neuroblastoma undergoing tandem transplants (hematopoietic stem cell…
- Conditions
- Transplant-Associated Thrombotic Microangiopathy, Neuroblastoma, High-risk Neuroblastoma, Thrombotic Microangiopathies
- Trial name
- NCT06182410
- Testing
- Defibrotide
- Sponsor
- University of California, San Francisco
Thrombotic Microangiopathies
Nomacopan (rVA576) in Transplant Associated Thrombotic Microangiopathy
Multicentre Study of nomacopan in Paediatric Haematopoietic Stem-Cell Transplant Associated Thrombotic Microangiopathy
- Trial name
- NCT04784455
- Testing
- nomacopan (rVA576)
- Where
- 9 sites in United States, Poland and 1 more
- Volunteers
- 10 people
- Sponsor
- AKARI Therapeutics
Thrombotic Microangiopathies, Hematologic Diseases
A Safety and Efficacy Study of NAC in Patients With TA-TMA
HSCT associated thrombotic microangiopathy(TA-TMA) is a heterogeneous, fatal disorder seen within 100 days post-transplant and presents with thrombocytopenia, hemolysis, acute renal failure, mental status changes and involvement…
- Trial name
- NCT03252925
- Testing
- N-Acetylcysteine
- Where
- China
- Volunteers
- 170 people
- Sponsor
- The First Affiliated Hospital of Soochow University